Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 3Neoplasms 3Kidney Neoplasms 3Carcinoma 3Pain 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2von Hippel-Lindau Disease 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Refractory Differentiated Thyroid Gland Carcinoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Lymphatic Metastasis 1Liver Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

TP protocol 2pembrolizumab 1cabozantinib 1Technetium 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Adjuvant 1Radiotherapy 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Indocyanine Green 1Control Groups 1Cobalt-60 1Cisplatin 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphatic Metastasis × cabozantinib × Clear all
NCT03793166 2026-05-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,175 enrolled
Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡